Biosimilars offer a cost-effective alternative to expensive biologic therapies, increasing access to treatment for patients worldwide. Their introduction can lead to significant savings for healthcare systems, allowing for the reallocation of resources to other areas of need. However, the successful integration of biosimilars into clinical practice depends on rigorous toxicological evaluations to ensure they meet high safety standards.
